We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...
We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...
Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...
An office and lab property in Thousand Oaks has sold in an all-cash transaction. Los Angeles-based Alta West Partners and an ...
A rare-disease federal incentive program critical to biotech R&D is in jeopardy, writes Leslie Williams, president and CEO of ...
US-based financial services company Vanguard Group acquired shares worth Rs 998 crore in seven Indian companies via open market transactions on the NSE. Concurrently, Zurich-based UBS Group AG sold ...
A rather odd week in venture, as the biggest rounds were raised by greentech, business travel and charity startups. Of course ...
An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.
Novo Nordisk's $1 billion bet last year on a small Canadian biotech could expand the Danish drug giant's arsenal of obesity medicines, but it will first have to address safety concerns. On Friday, Nov ...
Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...
Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback